DNA Repair Drugs Market – Breakthrough for Cancer Patients
DNA repair drugs are used in repairing damaged DNA and for treating cancers. DNA damage results in genetic disorders, however the human body has its own mechanisms to correct the DNA sequence. DNA repair drugs such as PARP inhibitors and other DNA repair drugs help to treat diseases with genetic aberrations.
The global DNA repair drugs market size was valued at US$ 461.3 Mn in 2017, and is expected to exhibit a CAGR of 32.4% over the forecast period (2018–2026).
Figure 1. Global DNA Repair Drugs Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2019)
Increasing incidence of cancer, rising government initiatives to promote awareness for cancer treatment, and expansion strategies by manufacturers to increase and expand their product portfolio in the international markets are factors propelling growth of the global DNA repair drugs market
Increasing incidence of cancer is expected to drive the global DNA repair drugs market growth over the forecast period. According to the World Cancer Research Fund International’s report in 2018, breast cancer accounted for the second highest number of cancer cases (2,088,849 new cases) across the globe in 2018. According to GLOBOCAN, 43.6% new cases of breast cancer were registered in Asia Pacific in 2018.
Moreover, increasing drug approval by key players in order to address demand for efficient therapeutics, is expected to propel growth of the market over the forecast period. In October 2018, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for Talazoparib (Talzenna) for treating patients with HER2 (negative locally advanced or metastatic breast cancer).
However, Delays in regulatory approvals lead to delay in marketing of the product, which can adversely affect the revenue generation of the manufacturer. Similarly, delay in post approval of the drug product for other therapeutic indication results in increasing clinical trials costs and can impact the labelling and approval status of currently marketed products.
Figure 2. Global DNA Repair Drugs Market Share (%), by Drug Type, (2018-2026)
Source: Coherent Market Insights Analysis (2019)
Rising prevalence of cancer, as well as increasing collaborations and acquisitions by key players is expected to boost the market growth
North America is expected to dominate the global DNA repair drugs market over the forecast period owing to increasing incidence of cancer. According to the American Cancer Society, in 2018, an estimated 266,120 new cases of invasive breast cancer were diagnosed in the U.S. Moreover, increasing demand for cancer treatments is expected to drive growth of the DNA repair drugs market in the region.
Market players are engaged in research and development activities in order to meet the rising demand DNA repair drugs. In May 2019, Clovis Oncology, Inc., collaborated with Bristol-Myers Squibb Company and Foundation Medicine Inc. to initiate phase II study for evaluating rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometroid ovarian cancer.
Major players operating in the global DNA repair drugs market are AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
DNA repair drugs such as Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna) are used for treating ovarian and breast cancer. These drugs fall under the category of Poly ADP-ribose Polymerase (PARP) inhibitors used as monotherapy in combination with other drugs for treatment of cancer.
Increasing incidences of cancer, increasing collaboration and acquisition with product launch by market players are major factors driving global DNA repair drugs market growth. In May 2019, AstraZeneca and Merck received the Health Canada approval for Lynparza as monotherapy maintenance treatment for patients with advanced high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer.
Furthermore, inorganic strategies adopted by key players to enhance their product portfolio is expected to drive the market growth. In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II trials to evaluate rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometrioid ovarian cancer.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 31 market data tables and 24 figures on "DNA Repair Drugs Market - Global forecast to 2026”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.